Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Abstract Objective: To quantify the association between olanzapine and diabetes. Design: Population based nested case-control study. Setting: United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000. Participants: 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls. Main outcome measures: Diagnosis and treatment of diabetes. Results: Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). Conclusion: Olanzapine is associated with a clinically important and significant increased risk of diabetes.

[1]  M. Knip,et al.  Valproate, lamotrigine, and insulin‐mediated risks in women with epilepsy , 1998, Annals of neurology.

[2]  D H Lawson,et al.  The General Practice Research Database. Scientific and Ethical Advisory Group. , 1998, QJM : monthly journal of the Association of Physicians.

[3]  E. Barrett-Connor,et al.  The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. , 1989, International journal of obesity.

[4]  S. Marder,et al.  Novel antipsychotics and new onset diabetes , 1998, Biological Psychiatry.

[5]  K. Brismar,et al.  Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. , 1999, The Journal of clinical psychiatry.

[6]  S. Shakir,et al.  The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England , 2001, Journal of psychopharmacology.

[7]  M. Lindquist,et al.  Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study , 2001, BMJ : British Medical Journal.

[8]  Jonathan M. Meyer.  A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.

[9]  M. Crismon,et al.  Olanzapine-Induced Glucose Dysregulation , 2000, The Annals of pharmacotherapy.

[10]  H. Gin,et al.  Diabetes as a result of atypical anti‐psychotic drugs – a report of three cases , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[11]  G. Colditz,et al.  Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women , 1995, Annals of Internal Medicine.

[12]  Bernstein Jg.  Psychotropic drug induced weight gain: mechanisms and management. , 1988 .

[13]  C. Correll,et al.  PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .

[14]  J. Lieberman,et al.  Drugs of the psychopharmacological revolution in clinical psychiatry. , 2000, Psychiatric services.

[15]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[16]  E. Thonnard-Neumann.  Phenothiazines and diabetes in hospitalized women. , 1968, The American journal of psychiatry.

[17]  J. Lindenmayer,et al.  Olanzapine-induced ketoacidosis with diabetes mellitus. , 1999, The American journal of psychiatry.

[18]  P. Howarth,et al.  Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels. , 1984, British journal of clinical pharmacology.

[19]  R. Hudak,et al.  Hyperglycemia and olanzapine. , 1999, The American journal of psychiatry.

[20]  K. Brismar,et al.  Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. , 2000, The Journal of clinical psychiatry.

[21]  L. Wood,et al.  The General Practice Research Database , 2004, Drug safety.

[22]  V. Wynn.  Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism. , 1982, American journal of obstetrics and gynecology.

[23]  P. S. Shelton,et al.  Hyperglycemia associated with olanzapine. , 1998, The Journal of clinical psychiatry.

[24]  J. Bernstein.  Psychotropic drug induced weight gain: mechanisms and management. , 1988, Clinical neuropharmacology.

[25]  David G. Kleinbaum,et al.  Logistic Regression. A Self- Learning Text , 1994 .

[26]  S. Ellis.  The metabolic effects of epinephrine and related amines. , 1956, Pharmacological reviews.

[27]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[28]  E. Goodall,et al.  A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced Obesity , 1988, British Journal of Psychiatry.

[29]  A Haines,et al.  Accuracy of diagnosis of psychosis on general practice computer system. , 1993, BMJ.